midazolam has been researched along with Cocaine Abuse in 7 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-one inhaled-cocaine abusers and 34 normal volunteers received either 1 mg intra-nasal midazolam or active placebo." | 6.73 | Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers. ( Bernik, M; Braun, IM; de Nucci, G; Tavares, H, 2008) |
| " We found that ketamine leads to significantly greater acute mystical-type effects (by Hood Mysticism Scale: HMS), dissociation (by Clinician Administered Dissociative States Scale: CADSS), and near-death experience phenomena (by the Near-Death Experience Scale: NDES), relative to the active control midazolam." | 5.27 | A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. ( Dakwar, E; Foltin, RW; Hart, CL; Hu, MC; Levin, FR; Nunes, EV, 2018) |
| " The mechanism of action analysis revealed that ketamine directly targets multiple CUD-associated genes (BDNF, CNR1, DRD2, GABRA2, GABRB3, GAD1, OPRK1, OPRM1, SLC6A3, SLC6A4) and pathways implicated in neuroactive ligand-receptor interaction, cAMP signaling and cocaine abuse/dependence." | 4.31 | Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses. ( Davis, PB; Gao, Z; Ghitza, UE; Gorenflo, M; Kaelber, DC; Winhusen, TJ; Xu, R, 2023) |
| "To evaluate the effects of pretreatment, midazolam (M), propofol (P), ziprasidone (Z), and two combinations of [(midazolam plus propofol (MP); midazolam plus ziprasidone (MZ)] in mice models in the prevention of seizures, and death due to acute cocaine toxicity." | 3.79 | Assessment of propofol, midazolam and ziprasidone, or the combinations for the prevention of acute cocaine toxicity in a mouse model. ( Erdur, B; Ergin, A; Kortunay, S; Yuksel, A, 2013) |
| "Cocaine toxicity results in cardiovascular complications, seizures, and death and accounts for approximately 20% of drug-related emergency department visits every year." | 3.75 | A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. ( Baladi, MG; Cooper, ZD; Jutkiewicz, EM; Narasimhan, D; Sunahara, RK; Woods, JH, 2009) |
| "The ketamine group was 53% less likely (hazard ratio=0." | 2.90 | A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. ( Basaraba, CN; Carpenter, KM; Choi, CJJ; Dakwar, E; Foltin, RW; Hart, CL; Levin, FR; Mathew, SJ; Nunes, EV; Pavlicova, M, 2019) |
| "Thirty-one inhaled-cocaine abusers and 34 normal volunteers received either 1 mg intra-nasal midazolam or active placebo." | 2.73 | Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers. ( Bernik, M; Braun, IM; de Nucci, G; Tavares, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z | 1 |
| Winhusen, TJ | 1 |
| Gorenflo, M | 1 |
| Ghitza, UE | 1 |
| Davis, PB | 1 |
| Kaelber, DC | 1 |
| Xu, R | 1 |
| Dakwar, E | 2 |
| Nunes, EV | 2 |
| Hart, CL | 2 |
| Hu, MC | 1 |
| Foltin, RW | 2 |
| Levin, FR | 2 |
| Mathew, SJ | 1 |
| Carpenter, KM | 1 |
| Choi, CJJ | 1 |
| Basaraba, CN | 1 |
| Pavlicova, M | 1 |
| Braun, IM | 1 |
| Tavares, H | 1 |
| de Nucci, G | 1 |
| Bernik, M | 1 |
| Jutkiewicz, EM | 1 |
| Baladi, MG | 1 |
| Cooper, ZD | 1 |
| Narasimhan, D | 1 |
| Sunahara, RK | 1 |
| Woods, JH | 1 |
| Shy, BD | 1 |
| Howland, MA | 1 |
| Hoffman, RS | 1 |
| Yuksel, A | 1 |
| Erdur, B | 1 |
| Kortunay, S | 1 |
| Ergin, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01535937] | Phase 1/Phase 2 | 55 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to An analysis demonstrated that running the final participants was unnecessary.) | ||
| Using the Behaviour Change Technique Taxonomy v1 to Conceptualize the Clinical Content of a Preliminary Randomised Controlled Study of an Online Mindfulness-based Cognitive Intervention for Chemsex[NCT05929040] | 29 participants (Actual) | Interventional | 2022-03-05 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Abstinence is defined as 2 or greater weeks of no cocaine use, as ascertained by the TLFB and urine toxicology. (NCT01535937)
Timeframe: Abstinence will be assessed over 4 weeks starting at the last day of week 1 and continuing through the end of study at the last day of week 5
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 13 |
| Midazolam | 3 |
Number of participants who use cocaine and drop from study. During phase 2, patients will be assessed twice weekly by TLFB and urine toxicology for cocaine use. The day of first use will determine the length of time that transpired from discharge to the first lapse onto cocaine. (NCT01535937)
Timeframe: Over the four week period following discharge from the inpatient unit at Day 5
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 16 |
| Midazolam | 26 |
3 trials available for midazolam and Cocaine Abuse
| Article | Year |
|---|---|
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.
Topics: Cocaine-Related Disorders; Dissociative Disorders; Female; Hallucinogens; Hospitalization; Humans; K | 2018 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers.
Topics: Administration, Intranasal; Adult; Area Under Curve; Case-Control Studies; Cocaine-Related Disorders | 2008 |
4 other studies available for midazolam and Cocaine Abuse
| Article | Year |
|---|---|
Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.
Topics: Antidepressive Agents; Artificial Intelligence; Cocaine; Cocaine-Related Disorders; Drug Repositioni | 2023 |
A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.
Topics: Animals; Anticonvulsants; Bacteria; Carboxylic Ester Hydrolases; Cocaine; Cocaine-Related Disorders; | 2009 |
Limited clinical value of bacterial cocaine esterase in cocaine toxicity.
Topics: Animals; Anticonvulsants; Carboxylesterase; Cocaine; Cocaine-Related Disorders; Humans; Midazolam; R | 2010 |
Assessment of propofol, midazolam and ziprasidone, or the combinations for the prevention of acute cocaine toxicity in a mouse model.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Cocaine-Related Disorders; Disease Models, Animal; D | 2013 |